Search Results
Aug 05, 2026, 06:25 ET CVS Health enhances its direct-to-consumer weight management offerings to improve access, affordability, care and support for GLP-1 medications
consumer access to prescription drugs is easier to deliver. For GLP-1s, it's simple for eligible patients to use our scheduler technology to connect with licensed clinicians 24 hours a day through MinuteClinic®, access GLP-1 medications through CVS Pharmacy®, receive personalized pharmacist
More news about: CVS Health
Aug 05, 2026, 03:00 ET Revolune and Propath UK Bring Service-Backed Multiplex immunofluorescence Workflows to Biopharma Customers
With more than 35 years of experience supporting translational research, biomarker development and regulated studies, Propath delivers high-quality, GLP and GCP-compliant services for both preclinical and clinical trial [email protected]
More news about: Revolune
Aug 05, 2026, 02:00 ET Revolune und Propath UK bieten ihren Kunden aus der Biopharma-Branche servicegestützte Workflows für die Multiplex-Immunfluoreszenz an
35 Jahren Erfahrung in der Unterstützung der translationalen Forschung, der Biomarker-Entwicklung und regulierter Studien bietet Propath hochwertige, GLP- und GCP-konforme Dienstleistungen sowohl für präklinische als auch für klinische Studienprogramme an.
More news about: Revolune
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
133)MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MariTide's long-acting design supports starting
More news about: Amgen
Aug 04, 2026, 15:08 ET Restore Hyper Wellness Encourages Americans to "Know Your Number" During National Wellness Month
Wellness Month initiatives.Clients who purchase an NAD+/NR Plan may receive a complimentary Fog Lifter IV, while those who purchase a GLP-1 Plan may receive a complimentary Lose It IV. These offers are available to eligible new and current clients and members. All medical plans and services
More news about: Restore Hyper Wellness
Aug 04, 2026, 14:00 ET LifeSpeak Appoints Neil King as Chief Executive Officer
without surveys or forms. The platform is configurable to whichever cost drivers an organization faces, including MSK, GLP-1, cardiometabolic health, mental health, and caregiving. It runs as a standalone member experience, embedded in a product a customer already owns,
More news about: LifeSpeak Inc.
Aug 04, 2026, 13:10 ET BluePill Launches World's First Marketplace to Recruit Synthetic Respondents: 1,000+ AI Twins of Real Buyers
data, that any brand can now talk to directly — live for the breakfast foods category. Pick the consumers you want — cereal brand loyalists, GLP-1 users, price-sensitive granola parents — the way you'd specify a sample from a panel vendor, then chat with them, survey them, or test concepts
More news about: BluePill Inc.
Aug 04, 2026, 10:01 ET Energy-Based Aesthetic Devices Market to Hit USD 29.39 Billion by 2036 Growing at 13.2%: Market Decipher
professional aesthetics, and the report's most consequential finding is a demand category that barely existed five years ago: GLP-1-associated skin laxity, a 'GLP-1 face' and body-laxity patient wave that could drive a USD 2 billion procedure opportunity by 2030.
More news about: Market Decipher
Aug 04, 2026, 07:30 ET Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
individual clinical needs, providers determine appropriate treatment pathways, which may include positional therapy, oral appliance therapy, CPAP therapy or GLP-1 treatment when clinically appropriate."Our goal is to connect members with the right care through one coordinated experience," said Lara Dodo,
More news about: DarioHealth Corp.
Aug 04, 2026, 01:25 ET Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa
a key focus for Innogen's overseas commercialization strategy.Efsubaglutide alfa is an innovative, human-derived, ultra-long-acting GLP-1 receptor agonist independently developed by Innogen Pharmaceuticals. It has been approved in Mainland China and Macau for the treatment of type
More news about: Innogen Pharmaceuticals
Aug 03, 2026, 12:48 ET As the GLP-1 Era Reshapes Weight Management, METAbiotics Launches with Science Designed to Support Long-Term Success
weight management and metabolic health. The launch comes as long-term weight maintenance emerges as one of the defining challenges of the GLP-1 era.
More news about: METAbiotics The Akkermansia Company
Aug 03, 2026, 12:00 ET Human Longevity Makes Clinical-Grade Whole Genome Sequencing Available to All for $599
10,000 genetic variants, flagging pharmacogenomic markers that affect how individuals respond to common medications including statins and GLP-1 receptor agonists, and screening for carrier status in hereditary conditions. The report also covers health-related traits across nutrition, metabolism,
More news about: Human Longevity, Inc.
Aug 03, 2026, 09:00 ET Andrew Ambrosy, Top Heart Doctor, Highlights GLP-1 and Dual GIP/GLP-1 Use for Lowering Risk of Cardiovascular Attack
2026 /PRNewswire/ -- Cardiologist Andrew P. Ambrosy, MD, MPH, today reminded heart patients of the benefits of taking a GLP-1 or dual GIP-GLP-1 inhibitor to reduce their risk of heart disease. These drugs include semaglutide (Wegovy) and tirzepatide (Zepbound). The
More news about: Andrew P. Ambrosy, MD, MPH
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥物，包括其核心項目ASC30，一款每日一次口服小分子GLP-1R激動劑，用於長期體重管理和糖尿病治療；ASC30_48FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC48（GIPR激動劑）的固定劑量復方制劑；ASC30_48_39FDC，一款每日一次口服小分子三靶點激動劑，為ASC30（GLP-1R激動劑）、ASC48（GIPR激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC39，一款與eloralintide類似、強效且對胰澱素具有選擇性的每日一次口服小分子胰澱素受體激動劑（SARA）；ASC30_39FDC，一款每日一次口服小分子雙靶點激動劑，為ASC30（GLP-1R激動劑）與ASC39（胰澱素選擇性受體激動劑（SARA））的固定劑量復方制劑；ASC36，一款胰澱素多肽，設計為每月一次至每季度一次皮下注射以及每日一次口服；ASC35，一款每月一次皮下注射GLP-1R/GIPR雙靶點激動劑多肽；ASC36_35FDC，一款每月一次皮下注射三靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC35（GLP-1R/GIPR激動劑）的固定劑量復方制劑；ASC37，一款GLP-1R/GIPR/GCGR三靶點激動劑多肽，設計為每月一次皮下注射及每日一次口服；以及ASC36_37FD），一款每月一次皮下注射四靶點多肽激動劑，為ASC36（胰澱素受體激動劑）與ASC37（GLP-1R/GIPR/GCGR激動劑）的固定劑量復方制劑，用於長期體重管理。歌禮已在香港聯交所上市（1672.HK）。欲瞭解更多信息，敬請登錄網站：
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
once-daily oral small molecule GLP-1, a first-in-class once-daily oral small molecule GLP-1/GIP dual agonist FDC (the first tirzepatide-like oral small molecule combination), a first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist FDC (the first
More news about: Ascletis Pharma Inc.
Jul 31, 2026, 07:00 ET Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy
validated across multiple clinical and preclinical programs, demonstrating exceptional ocular tolerability and minimal systemic exposure in extensive GLP toxicology studies.About Proliferative Vitreoretinopathy (PVR)Proliferative Vitreoretinopathy (PVR) is the leading cause of surgical
More news about: Ractigen Therapeutics
Jul 30, 2026, 10:14 ET Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
Insulin Injection Market ContextThe global insulin delivery device market has been undergoing structural change. Pump adoption and GLP-1 therapies have reshaped patient purchasing patterns, particularly in the United States. The complaint alleges that Embecta repeatedly
More news about: SueWallSt.com
Jul 30, 2026, 10:09 ET Lost Money on Embecta Corp. (EMBC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
Insulin Injection Market ContextThe global insulin delivery device market has been undergoing structural change. Pump adoption and GLP-1 therapies have reshaped patient purchasing patterns, particularly in the United States. The complaint alleges that Embecta repeatedly
More news about: SueWallSt.com
Jul 30, 2026, 10:02 ET Capsa Healthcare Introduces the Pharmacy Engine: RoboPharma, Powered by Axona
running multi-tenant from order intake through shipmentSpecialty and direct-to-patient fulfillment: including cold chain, GLP-1 and unit-of-use packagingWarehouse and enterprise distribution: receiving, put-away, picking and outbound across the network from
More news about: Capsa Healthcare
Jul 30, 2026, 10:00 ET New Study: Independent Grocers Demonstrated Resilience Amid Economic Uncertainty
reflecting the wave of capital projects completed earlier in the decade. Consumer interest in health, protein, ingredient transparency and GLP-1-related eating patterns continued to create new opportunities in fresh foods and perimeter departments.Artificial intelligence is moving from
More news about: FMS Solutions
Jul 30, 2026, 08:25 ET Health-E Commerce® Expands Beyond E-Commerce with Launch of Patiently™ Telehealth Platform Offering Personalized, FSA/HSA Eligible Weight Loss and Menopause Support
Patiently™ launches with two of today's fastest-growing telehealth categories: GLP-1s for medical weight loss and hormone replacement therapy (HRT) for perimenopause and menopause support. By integrating with FSA Store® and
More news about: Health-E Commerce
Jul 30, 2026, 07:30 ET Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
supported members on GLP-1 therapy for years through AI-powered engagement, connected monitoring, nutrition and behavioral coaching. Now, with Beluga's network of licensed healthcare providers, Dario delivers medical evaluation, prescribing of FDA-approved GLP-1 medications where clinically
More news about: DarioHealth Corp.
Jul 29, 2026, 16:05 ET Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
year. Oral VK2735 is positioned to potentially become the first orally available dual GLP-1/GIP agonist to reach the market, potentially offering a competitive advantage compared to GLP-1 mono-agonist oral products currently available. Viking's novel maintenance dosing study also
More news about: Viking Therapeutics, Inc.
Jul 29, 2026, 14:00 ET NABP to Develop National Adverse Event Reporting Clearinghouse for Compounded Medications
our member boards and the FDA, we intend to champion it."In its comments to PCAC, NABP described how the recent surge in compounded GLP-1 medications and evolving business models has pushed compounding far past the small-scale, patient-specific model the current regulatory framework
More news about: National Association of Boards of Pharmacy
Jul 29, 2026, 13:14 ET GMP Biologics Market to Reach US$98.2 Bn by 2033 Accelerates with Biopharmaceutical Innovation - Persistence Market Research
acquisition broadens its service portfolio beyond existing biologics manufacturing into peptide-based therapeutics, including rapidly growing GLP-1 therapies for obesity and diabetes.The acquisition reflects the increasing strategic importance of peptide manufacturing within the
More news about: Persistence Market Research Pvt. Ltd.